SCHEMBL21872988

SCHEMBL21872988

Cc1nc(-c2cnc(NC(C)C)n(C)c2=O)ccc1Cc1cn(C(=O)OC(C)(C)C)c2ncccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 5/20 0.42
▸ PDGFRB P09619 3/20 0.42
▸ PDGFRA P16234 3/20 0.42
▸ LCK P06239 1/20 0.42
▸ KIT P10721 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ PTK6 Q13882 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ TYK2 P29597 2/20 0.32
▸ DTYMK P23919 1/20 0.31
▸ PDE4A P27815 2/20 0.31
▸ KCNH2 Q12809 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ ELANE P08246 1/20 0.31
▸ DHODH Q02127 1/20 0.31
▸ CCNB2 O95067 2/20 0.31
▸ CDK1 P06493 2/20 0.31
▸ CCNB1 P14635 2/20 0.31
▸ CCNB3 Q8WWL7 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21906312 0.90 CSF1R (0.43) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL21873056 0.86 CSF1R (0.44) CSF1RPDGFRBPDGFRAFLT3L3MBTL1
SCHEMBL21873003 0.77 GPR84 (0.45) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL21873038 0.76 CSF1R (0.43) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL28337392 0.76 CSF1R (0.45) CSF1RPDGFRBPDGFRAFLT3TYK2
SCHEMBL22978451 0.76 L3MBTL1 (0.41) L3MBTL1DTYMKELANEPDE10A
SCHEMBL22978450 0.73 ELANE (0.39) CYP2C9L3MBTL1DTYMKELANE
SCHEMBL21873026 0.70 CYP2C9 (0.44) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL4505573 0.69 L3MBTL1 (0.39) L3MBTL1DTYMKELANEPDE10A
SCHEMBL4572234 0.69 L3MBTL1 (0.46) L3MBTL1DTYMKELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRB 149/4885PDGFRA 229/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRB 149/4885PDGFRA 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback